ketamine has been researched along with Acquired Metabolic Diseases, Brain in 1 studies
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boneh, A | 1 |
| Degani, Y | 1 |
| Harari, M | 1 |
1 other study available for ketamine and Acquired Metabolic Diseases, Brain
| Article | Year |
|---|---|
Prognostic clues and outcome of early treatment of nonketotic hyperglycinemia.
Topics: Amino Acid Metabolism, Inborn Errors; Benzoates; Benzoic Acid; Brain Diseases, Metabolic; Child, Pre | 1996 |